Skip to main content

Advertisement

SpringerLink
Log in

Salvage chemotherapy for metastatic and recurrent ependymoma of childhood

  • Invited Paper
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Introduction

Chemotherapy has limited role in the up-front management of ependymoma. At the time of recurrence, the role of chemotherapy is also ill defined and the choice of chemotherapeutic agents is often arbitrary, based on anecdotal data and personal experience.

Methods

The purpose of this review is to describe and critically analyze the published literature on chemotherapy in patients with recurrent and metastatic ependymoma.

Discussion

The disappointing response rate with single agents (12.9%) and combinations (17.4%) emphasizes the need to re-evaluate the current chemotherapeutic approach of intracranial ependymoma, and biological studies are needed to identify targets that may be considered for clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Allen J, Packer R, Bleyer A, Zeltzer P, Prados M, Nirenberg A (1991) Recombinant interferon beta: a phase I–II trial in children with recurrent brain tumors. J Clin Oncol 9:783–788

    PubMed  CAS  Google Scholar 

  2. Allen JC, Helson L (1981) High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55:749–756

    Article  PubMed  CAS  Google Scholar 

  3. Allen JC, Hancock C, Walker R, Tan C (1987) PCNU and recurrent childhood brain tumors. J Neuro Oncol 5:241–244

    Article  CAS  Google Scholar 

  4. Barone G, Maurizi P, Tamburrini G, Riccardi R (2006) Role of temozolomide in pediatric brain tumors. Childs Nerv Syst 22:652–661

    Article  PubMed  Google Scholar 

  5. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42:2335–2342

    Article  PubMed  CAS  Google Scholar 

  6. Ben Arush MW, Postovsky S, Goldsher D, el Hasid R, Constantini S (1999) Clinical and radiographic response in three children with recurrent malignant cerebral tumors with high-dose tamoxifen. Pediatr Hematol Oncol 16:245–250

    Article  PubMed  CAS  Google Scholar 

  7. Bertolone SJ, Baum ES, Krivit W, Hammond GD (1989) A phase II study of cisplatin therapy in recurrent childhood brain tumors. A report from the Children’s Cancer Study Group. J Neuro Oncol 7:5–11

    Article  CAS  Google Scholar 

  8. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM (2003) Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21:143–147

    Article  PubMed  CAS  Google Scholar 

  9. Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM (2006) A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Canc 46:50–55

    Article  CAS  Google Scholar 

  10. Bouffet E, Perilongo G, Canete A, Massimino M (1998) Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30:319–329, discussion 329–331

    Article  PubMed  CAS  Google Scholar 

  11. Brandes AA, Cavallo G, Reni M, Tosoni A, Nicolardi L, Scopece L, Franceschi E, Sotti G, Talacchi A, Turazzi S, Ermani M (2005) A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer 104:143–148

    Article  PubMed  Google Scholar 

  12. Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A (2007) Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13:6712–6718

    Article  PubMed  CAS  Google Scholar 

  13. Butler WE, Khan A, Khan SA (2002) Posterior fossa ependymoma with intense but transient disseminated enhancement but not metastasis. Pediatr Neurosurg 37:27–31

    Article  PubMed  Google Scholar 

  14. Castleberry RP, Ragab AH, Steuber CP, Kamen B, Toledano S, Starling K, Norris D, Burger P, Krischer JP (1990) Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study. Investig New Drugs 8:401–406

    CAS  Google Scholar 

  15. Chamberlain MC, Prados MD, Silver P, Levin VA (1988) A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors. J Neuro Oncol 6:319–323

    Article  CAS  Google Scholar 

  16. Chamberlain MC (2001) Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol 24:117–121

    Article  PubMed  CAS  Google Scholar 

  17. Chastagner P, Sommelet-Olive D, Kalifa C, Brunat-Mentigny M, Zucker JM, Demeocq F, Baranzelli MC, Tron P, Bergeron C, Pein F et al (1993) Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 21:49–53

    Article  PubMed  CAS  Google Scholar 

  18. Comi AM, Backstrom JW, Burger PC, Duffner PK (1998) Clinical and neuroradiologic findings in infants with intracranial ependymomas. Pediatric Oncology Group. Pediatr Neurol 18:23–29

    Article  PubMed  CAS  Google Scholar 

  19. Corden BJ, Strauss LC, Killmond T, Carson BS, Wharam MD, Kumar AJ, Piantadosi S, Robb PA, Phillips PC (1991) Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neuro Oncol 11:57–63

    Article  CAS  Google Scholar 

  20. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC (2005) Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 23:6172–6180

    Article  PubMed  CAS  Google Scholar 

  21. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A (2006) Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Canc 47:30–36

    Article  Google Scholar 

  22. Dorr RT, Salmon SE, Robertone A, Bonnem E (1988) Phase I–II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days. J Interferon Res 8:717–725

    PubMed  CAS  Google Scholar 

  23. Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, McCluggage CW, Burger PC, Kepner J, Heideman RL (2003) Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol 5:261–267

    Article  PubMed  CAS  Google Scholar 

  24. Ettinger LJ, Sinniah D, Siegel SE, Fishman LS, Segall HD, Soni D, Bennetts GA, Schultz DH, Raphael D (1985) Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) in children with brain tumors. J Neuro Oncol 3:263–269

    Article  CAS  Google Scholar 

  25. Ettinger LJ, Ru N, Krailo M, Ruccione KS, Krivit W, Hammond GD (1990) A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: a report from the Children’s Cancer Study Group. J Neuro Oncol 9:69–76

    Article  CAS  Google Scholar 

  26. Feun LG, Stewart DJ, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Bodey GP (1983) A phase II trial of 1-(2-chloroethyl)-3-(2, 6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors. J Neuro Oncol 1:45–48

    CAS  Google Scholar 

  27. Foreman NK, Love S, Gill SS, Coakham HB (1997) Second-look surgery for incompletely resected fourth ventricle ependymomas: technical case report. Neurosurg 40:856–860, discussion 860

    Article  CAS  Google Scholar 

  28. Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806–4812

    Article  PubMed  CAS  Google Scholar 

  29. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS (1999) Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res 5:3956–3962

    PubMed  CAS  Google Scholar 

  30. Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, Falletta JM, Norris D, Ragab AH, Mahoney DH Jr et al (1992) Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 10:249–256

    PubMed  CAS  Google Scholar 

  31. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, Bigner DD, Schold SC Jr (1995) Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55:2853–2857

    PubMed  CAS  Google Scholar 

  32. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD (1990) Carboplatin in childhood brain tumors. A Children's Cancer Study Group phase II trial. Cancer 66:2465–2469

    Article  PubMed  CAS  Google Scholar 

  33. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW (2002) ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8:3054–3064

    PubMed  CAS  Google Scholar 

  34. Goldwein JW, Glauser TA, Packer RJ, Finlay JL, Sutton LN, Curran WJ, Laehy JM, Rorke LB, Schut L, D'Angio GJ (1990) Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer 66:557–563

    Article  PubMed  CAS  Google Scholar 

  35. Gornet MK, Buckner JC, Marks RS, Scheithauer BW, Erickson BJ (1999) Chemotherapy for advanced CNS ependymoma. J Neuro Oncol 45:61–67

    Article  CAS  Google Scholar 

  36. Grill J, Kalifa C, Doz F, Schoepfer C, Sainte-Rose C, Couanet D, Terrier-Lacombe MJ, Valteau-Couanet D, Hartmann O (1996) A high-dose busulfan–thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study. Pediatr Neurosurg 25:7–12

    Article  PubMed  CAS  Google Scholar 

  37. Hargrave DR, Bouffet E, Gammon J, Tariq N, Grant RM, Baruchel S (2002) Phase I study of fotemustine in pediatric patients with refractory brain tumors. Cancer 95:1294–1301

    Article  PubMed  CAS  Google Scholar 

  38. Heideman RL, Packer RJ, Reaman GH, Allen JC, Lange B, Horowitz ME, Steinberg SM, Gillespie A, Kovnar EH, Balis FM et al (1993) A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 72:271–275

    Article  PubMed  CAS  Google Scholar 

  39. Heideman RL, Douglass EC, Langston JA, Krischer JP, Burger PC, Kovnar EH, Kun LE, Friedman HS, Kadota R (1995) A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. J Neuro Oncol 25:77–84

    Article  CAS  Google Scholar 

  40. Hodgson DC, Goumnerova LC, Loeffler JS, Dutton S, Black PM, Alexander E 3rd, Xu R, Kooy H, Silver B, Tarbell NJ (2001) Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys 50:929–935

    Article  PubMed  CAS  Google Scholar 

  41. Hongeng S, Brent TP, Sanford RA, Li H, Kun LE, Heideman RL (1997) O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin Cancer Res 3:2459–2463

    PubMed  CAS  Google Scholar 

  42. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R (2001) Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. J Pediatr Hematol Oncol 23:277–281

    Article  PubMed  CAS  Google Scholar 

  43. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC (2008) Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 26:4921–4927

    Article  PubMed  CAS  Google Scholar 

  44. Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T (2006) Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. Clin Cancer Res 12:516–522

    Article  PubMed  CAS  Google Scholar 

  45. Kadota RP, Stewart CF, Horn M, Kuttesch JF Jr, Burger PC, Kepner JL, Kun LE, Friedman HS, Heideman RL (1999) Topotecan for the treatment of recurrent or progressive central nervous system tumors—a pediatric oncology group phase II study. J Neuro Oncol 43:43–47

    Article  CAS  Google Scholar 

  46. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE (2007) Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 25:3137–3143

    Article  PubMed  CAS  Google Scholar 

  47. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T (2008) Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Canc 52:169–176

    Article  Google Scholar 

  48. Lassaletta A, Perez-Olleros P, Scaglione C, Sirvent S, De Prada I, Perez-Martinez A, Ruiz-Hernandez A, Madero L (2007) Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J Neuro Oncol 83:303–306

    Article  CAS  Google Scholar 

  49. Levin VA, Edwards MS, Gutin PH, Vestnys P, Fulton D, Seager M, Wilson CB (1984) Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. J Neurosurg 61:1063–1068

    Article  PubMed  CAS  Google Scholar 

  50. Lowis S, Lewis I, Elsworth A, Weston C, Doz F, Vassal G, Bellott R, Robert J, Pein F, Ablett S, Pinkerton R, Frappaz D (2006) A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer 95:571–580

    Article  PubMed  CAS  Google Scholar 

  51. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26:919–924

    Article  PubMed  CAS  Google Scholar 

  52. Madden JR, Fenton LZ, Weil M, Winston KR, Partington M, Foreman NK (2001) Experience with tamoxifen/etoposide in the treatment of a child with myxopapillary ependymoma. Med Pediatr Oncol 37:67–69

    Article  PubMed  CAS  Google Scholar 

  53. Mason WP, Goldman S, Yates AJ, Boyett J, Li H, Finlay JL (1998) Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma—a report of the Children's Cancer Group. J Neuro Oncol 37:135–143

    Article  CAS  Google Scholar 

  54. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, Lichter P (2006) Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12:2070–2079

    Article  PubMed  CAS  Google Scholar 

  55. Merchant TE, Fouladi M (2005) Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neuro Oncol 75:287–299

    Article  Google Scholar 

  56. Merchant TE, Boop FA, Kun LE, Sanford RA (2008) A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys 71:87–97

    PubMed  Google Scholar 

  57. Mulne AF, Ducore JM, Elterman RD, Friedman HS, Krischer JP, Kun LE, Shuster JJ, Kadota RP (2000) Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 22:41–44

    Article  PubMed  CAS  Google Scholar 

  58. Naylor B (1964) The cytologic diagnosis of cerebrospinal fluid. Acta Cytol 8:141–149

    PubMed  CAS  Google Scholar 

  59. Needle MN, Molloy PT, Geyer JR, Herman-Liu A, Belasco JB, Goldwein JW, Sutton L, Phillips PC (1997) Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 29:28–32

    Article  PubMed  CAS  Google Scholar 

  60. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110:1542–1550

    Article  PubMed  CAS  Google Scholar 

  61. Ragab AH, Burger P, Badnitsky S, Krischer J, Van Eys J (1986) PCNU in the treatment of recurrent medulloblastoma and ependymoma—a POG Study. J Neuro Oncol 3:341–342

    Article  CAS  Google Scholar 

  62. Ramachandran C, Khatib Z, Petkarou A, Fort J, Fonseca HB, Melnick SJ, Escalon E (2004) Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neuro Oncol 67:19–28

    Article  Google Scholar 

  63. Razzouk BI, Heideman RL, Friedman HS, Jenkins JJ, Kun LE, Fairclough DL, Horowitz ME (1995) A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer 75:2762–2767

    Article  PubMed  CAS  Google Scholar 

  64. Rehman S, Brock C, Newlands ES (2006) A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy. Am J Clin Oncol 29:106–107

    Article  PubMed  Google Scholar 

  65. Rezai AR, Woo HH, Lee M, Cohen H, Zagzag D, Epstein FJ (1996) Disseminated ependymomas of the central nervous system. J Neurosurg 85:618–624

    Article  PubMed  CAS  Google Scholar 

  66. Rodriguez LA, Prados M, Silver P, Levin VA (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64:2420–2423

    Article  PubMed  CAS  Google Scholar 

  67. Sandri A, Massimino M, Mastrodicasa L, Sardi N, Bertin D, Basso ME, Todisco L, Paglino A, Perilongo G, Genitori L, Valentini L, Ricardi U, Gandola L, Giangaspero F, Madon E (2005) Treatment with oral etoposide for childhood recurrent ependymomas. J Pediatr Hematol Oncol 27:486–490

    Article  PubMed  Google Scholar 

  68. Sardi I, Sanzo M, Giordano F, Sandri A, Mussa F, Donati PA, Genitori L (2008) Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma. Oncol Rep 19:1219–1223

    PubMed  CAS  Google Scholar 

  69. Schiavetti A, Varrasso G, Maurizi P, Cappelli C, Clerico A, Properzi E, Castello MA (2000) Ten-day schedule oral etoposide therapy in advanced childhood malignancies. J Pediatr Hematol Oncol 22:119–124

    Article  PubMed  CAS  Google Scholar 

  70. Sexauer CL, Khan A, Burger PC, Krischer JP, van Eys J, Vats T, Ragab AH (1985) Cisplatin in recurrent pediatric brain tumors. A POG Phase II study. A Pediatric Oncology Group Study. Cancer 56:1497–1501

    Article  PubMed  CAS  Google Scholar 

  71. Slavc I, Schuller E, Falger J, Gunes M, Pillwein K, Czech T, Dietrich W, Rossler K, Dieckmann K, Prayer D, Hainfellner J (2003) Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neuro Oncol 64:239–247

    Article  Google Scholar 

  72. Souweidane MM, Bouffet E, Finlay J (1998) The role of chemotherapy in newly diagnosed ependymoma of childhood. Pediatr Neurosurg 28:273–278

    Article  PubMed  CAS  Google Scholar 

  73. Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C (2006) Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol 24:1522–1528

    Article  PubMed  CAS  Google Scholar 

  74. Tabori U, Wong V, Ma J, Shago M, Alon N, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C (2008) Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer 99:1129–1135

    Article  PubMed  CAS  Google Scholar 

  75. Tam JK, Bradley WG Jr, Goergen SK, Chen DY, Pema PJ, Dubin MD, Teresi LM, Jordan JE (1996) Patterns of contrast enhancement in the pediatric spine at MR imaging with single- and triple-dose gadolinium. Radiol 198:273–278

    CAS  Google Scholar 

  76. Taylor SA, McCracken JD, Eyre HJ, O'Bryan RM, Neilan BA (1985) Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study. J Neuro Oncol 3:131–135

    Article  CAS  Google Scholar 

  77. Timmermann B, Kortmann RD, Kuhl J, Meisner C, Slavc I, Pietsch T, Bamberg M (2000) Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 46:287–295

    Article  PubMed  CAS  Google Scholar 

  78. Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS (2002) Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol 4:102–108

    Article  PubMed  CAS  Google Scholar 

  79. Valera ET, Machado HR, Santos AC, de Oliveira RS, Araujo D, Neder L, Tone LG (2005) The use of neoadjuvant chemotherapy to achieve complete surgical resection in recurring supratentorial anaplastic ependymoma. Childs Nerv Syst 21:230–233

    Article  PubMed  Google Scholar 

  80. Walker RW, Allen JC (1988) Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6:62–66

    PubMed  CAS  Google Scholar 

  81. Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM (2005) Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 23:7646–7653

    Article  PubMed  CAS  Google Scholar 

  82. Weitman S, Ochoa S, Sullivan J, Shuster J, Winick N, Pratt C, Vietti T, Harris M (1997) Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 19:187–191

    Article  PubMed  CAS  Google Scholar 

  83. Wiener MD, Boyko OB, Friedman HS, Hockenberger B, Oakes WJ (1990) False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. AJNR Am J Neuroradiol 11:1100–1103

    PubMed  CAS  Google Scholar 

  84. Yoffe R, Khakoo Y, Dunkel IJ, Souweidane M, Lis E, Sklar C (2007) Recurrent ependymoma treated with high-dose tamoxifen in a peripubertal female: impact on tumor and the pituitary–ovarian axis. Pediatr Blood Canc 49:758–760

    Article  Google Scholar 

  85. Zacharoulis S, Levy A, Chi SN, Gardner S, Rosenblum M, Miller DC, Dunkel I, Diez B, Sposto R, Ji L, Asgharzadeh S, Hukin J, Belasco J, Dubowy R, Kellie S, Termuhlen A, Finlay J (2007) Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49:34–40

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paediatric Neuro-Oncology Program, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G1X8, Canada

    Eric Bouffet & Ute Bartels

  2. Department of Paediatric Oncology/Haematology, Our Lady’s Children’s Hospital, Crumlin, Dublin 12, Ireland

    Michael Capra

Authors
  1. Eric Bouffet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Capra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ute Bartels
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Bouffet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bouffet, E., Capra, M. & Bartels, U. Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. Childs Nerv Syst 25, 1293–1301 (2009). https://doi.org/10.1007/s00381-009-0883-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-009-0883-x

Keywords

Search

Navigation